CASI Pharmaceuticals Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
86.59 M |
Public Float |
49.44 M |
CASI Pharmaceuticals Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$0.35 |
Market Cap |
$292.89 M |
Shares Outstanding |
95.72 M |
Public Float |
41.25 M |
Address |
9620 Medical Center Drive Rockville Maryland 20850 United States |
Employees | - |
Website | http://www.casipharmaceuticals.com |
Updated | 07/08/2019 |
CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs with commercial focus on the China market. The firm develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong and Macau. The drugs are Captisol-Enabled, ZEVALIN and MARQIBO. |